

MAMMAPRINT RISK GROUP

High Risk 2




Your care team has ordered the MammaPrint® and Blueprint® tests for your tumor. These tests help to better understand the biology of your tumor, providing important information to create the most personalized and informed treatment recommendation for you.



MAMMAPRINT+BLUEPRINT

Illuminating Tumor Biology

High Risk 2



Treatment Options

CHEMOTHERAPY

Studies have shown that tumors in the High Risk 2 range of the MammaPrint Index have a higher chance of the cancer returning within five years of diagnosis.¹ They have also shown that chemotherapy may help reduce this risk.² Talk to your healthcare provider about whether chemotherapy is appropriate for you, and how Blueprint may help further personalize your treatment plan.

HORMONAL THERAPY

For most hormone-positive tumors, the standard treatment includes taking hormone therapy for five years.³ For MammaPrint High Risk 2 tumors, studies suggest continuing hormonal therapy beyond five years is generally not necessary.^{4,5} Discuss your treatment plan and options with your provider to ensure it aligns with your individual needs.

MammaPrint and Blueprint are two tests that work together to provide your care team with valuable insights into your tumor. These tests should be considered alongside other clinical and pathological information in partnership with your medical team. Please consult your test results for more detailed information and your care team when making decisions about your treatment.

Scan here to
continue learning
about MammaPrint
and Blueprint



MKT-209-V1

1. Cardoso F, van't Veer LJ, Bogaerts J, et al. J Clin Oncol. 2021
2. Brufsky A et al. 2024. SABCS. PS-08-12.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024.
4. Rastogi P et al. J Clin Oncol. 2024;00:1-9.
5. van't Veer LJ, et al. JAMA. November 2024

